First wave of Revlimid competition hits shelves in USA

8 September 2022
dr-reddys-largepng

Indian drugmaker Dr Reddy’s Laboratories (BSE: 500124) has launched a generic version of Bristol Myers Squibb’s (NYSE: BMY) cancer drug Revlimid (lenalidomide).

The company said it was undertaking a “volume-limited launch,” and was eligible for 180 days of first-to-market generic drug exclusivity.

The launch comes after the company agreed with Celgene, the New York-based company acquired in 2019 by Bristol Myers, terms for a license to sell volume-limited amounts in the USA as part of a litigation settlement.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Generics